TITLE

A Risk-Benefit Assessment of Metformin in Type 2 Diabetes Mellitus

AUTHOR(S)
Howlett, H.C.S.; Bailey, C.J.
PUB. DATE
June 1999
SOURCE
Drug Safety;Jun1999, Vol. 20 Issue 6, p489
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Metformin has been used for over 40 years as an effective glucose-lowering agent in type 2 (noninsulin-dependent) diabetes mellitus. Typically it reduces basal and postprandial hyperglycaemia by about 25% in more than 90% of patients when either given alone or coadministered with other therapies including insulin during a programme of managed care. Metformin counters insulin resistance and offers benefits against many features of the insulin resistance syndrome (Syndrome X) by preventing bodyweight gain, reducing hyperinsulinaemia and improving the lipid profile. In contrast to sulphonylureas, metformin does not increase insulin secretion or cause serious hypoglycaemia. Treatment of type 2 diabetes mellitus with metformin from diagnosis also offers greater protection against the chronic vascular complications of type 2 diabetes mellitus. The most serious complication associated with metformin is lactic acidosis which has an incidence of about 0.03 cases per 1000 patients years of treatment and a mortality risk of about 0.015 per 1000 patient-years. Most cases occur in patients who are wrongly prescribed the drug, particularly patients with impaired renal function (e.g. serum creatinine level >130 µmol/L or >1.5 g/L). Other major contraindications include congestive heart failure, hypoxic states and advanced liver disease. Serious adverse events with metformin are predictable rather than spontaneous and are potentially preventable if the prescribing guidelines are respected. Gastrointestinal adverse effects, notably diarrhoea, occur in less than 20% of patients and remit when the dosage is reduced. The life-threatening risks associated with metformin are rare and could mostly be avoided by strict adherence to the prescribing guidelines. Given the 4 decades of clinical experience with metformin, its antihyperglycaemic efficacy and benefits against Syndrome X, metformin offers a very favourable risk-benefit assessment when compared with the chronic morbidity and premature mortality among patients with type 2 diabetes mellitus.
ACCESSION #
9526578

 

Related Articles

  • The Antihyperglycaemic Effect of Metformin: Therapeutic and Cellular Mechanisms. Wiernsperger, N.F.; Bailey, C.J. // Drugs;Dec1999 Supplement 1, Vol. 58 Issue 6, p31 

    Metformin is regarded as an antihyperglycaemic agent because it lowers blood glucose concentrations in type 2 (non-insulin-dependent) diabetes without causing overt hypoglycaemia. Its clinical efficacy requires the presence of insulin and involves several therapeutic effects. Of these effects,...

  • Hemodynamic Effects of Acute Hyperglycemia in Type 2 Diabetic Patients. Marfella, Raffaele; Nappo, Francesco; De Angelis, Lorenita; Paolisso, Giuseppe; Tagliamonte, Maria Rosaria; Giugliano, Dario // Diabetes Care;May2000, Vol. 23 Issue 5, p658 

    Focuses on a study which evaluated the hemodynamic effects of acute hyperglycemia in type 2 diabetic patients and to see whether these effects are related to changes in nitric oxide availability. Research design and methods; Results; Conclusions.

  • The Efficacy of Acarbose in the Treatment of Patients with non-Insulin-dependent Diabetes Mellitus. Chiasson, Jean Louis; Josse, Robert G.; Hunt, John A.; Palmason, Carol; Rodger, N. Wilson; Ross, Stuart A.; Ryan, Edmond A.; Tan, Meng H.; Wolever., Thomas M.S. // Annals of Internal Medicine;12/15/94, Vol. 121 Issue 12, p928 

    Presents a study which evaluated the long-term efficacy of acarbose, an alpha-glucosidase inhibitor, in improving glycemic control in patients with non-insulin-dependent diabetes mellitus. Alternative approach to the problem of postprandial hyperglycemia; Methods used in the study; Results and...

  • Morning Hyperglycemic Excursions. Monnier, Louis; Rabasa-Lhoret, Remy; Lapinski, Helene; Caubel, Cecile; Avignon, Antoine; Boniface, Helene; Colette, Claude // Diabetes Care;Apr2002, Vol. 25 Issue 4, p737 

    Presents a study that determined whether, over daytime, one or several hyperglycemic excursions exist that can be general failures in the glycemic control of patients with type 2 diabetes. Protocol of the study and analytical procedures; Comparison of plasma glucose and insulin concentrations...

  • Type 2 Diabetes Impairs Splanchnic Uptake of Glucose but Does Not Alter Intestinal Glucose Absorption During Enteral Glucose Feeding. Basu, Ananda; Basu, Rita; Shah, Pankaj; Vella, Adrian; Johnson, C. Michael; Jensen, Michael; Nair, K. Sreekumaran; Schwenk, W. Frederick; Rizza, Robert A. // Diabetes;Jun2001, Vol. 50 Issue 6, p1351 

    Focuses on the effects of diabetes on the splanchnic uptake of glucose. Decrease in the contribution of extracellular pathway to hepatic glycogen synthesis; Role of abnormal hepatic and muscle glucose metabolism on postprandial hyperglycemia; Characterization of type 2 diabetes.

  • Managing hyperglycemia in Type 2 diabetes: Here's how. Fernandez, Julio // Drug Topics;9/18/2006, Vol. 150 Issue 18, p25 

    The article presents an instructional material on the management of hyperglycemia in patients with non-insulin-dependent diabetes.

  • Erratum to: Canagliflozin: First Global Approval. Elkinson, Shelley; Scott, Lesley J. // Drugs;Nov2013, Vol. 73 Issue 16, p1847 

    A correction to the article "Canagliflozin: First Global Approval" that was published in the October 2013 issue is presented.

  • Comment on: Raz et al. Personalized Management of Hyperglycemia in Type 2 Diabetes: Reflections Froma Diabetes Care Editors' Expert Forum. GIUGLIANO, DARIO; ESPOSITO, KATHERINE // Diabetes Care;Nov2013, Vol. 36 Issue 11, pe192 

    A letter to the editor is presented in response to the article "Personalized management of hyperglycemia in type 2 diabetes: reflections from a "Diabetes Care" Editors' Expert Forum," by I. Raz and colleagues in the 2013 issue.

  • Lipoperoxidation and antioxidant capacity in patients with poorly controlled type 2 diabetes. Lodovici, M.; Bigagli, E.; Bardini, G.; Rotella, C. M. // Toxicology & Industrial Health;May/Jun2009, Vol. 25 Issue 4/5, p337 

    Type 2 diabetes is a heterogeneous disease resulting from insulin resistance and/or from a β-cell secretory defect. Hyperglycemia, which occurs during type 2 diabetes, causes disorders of oxidative- antioxidative balance in the cells, leading to increased free-radical formation. Reduced...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics